Evommune (EVMN) Cash from Operations (2024 - 2026)
Evommune (EVMN) posted quarterly Cash from Operations of 27503000.0 for Q1 2026, down 15.08% year-over-year from 32387001.58 in Q1 2025, and down 64.7% quarter-over-quarter from 16699000.0 in Q4 2025.
Powered by 
Analysis
Evommune (EVMN) Cash from Operations (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Cash from Operations for 3 consecutive years, with 27503000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 15.08% year-over-year to 27503000.0; the TTM figure through Mar 2026 stood at 86613000.0 (changed N/A YoY), while the FY2025 annual figure was 76441000.0, down 31.35% from the prior year.
- Cash from Operations declined to 27503000.0 in Q1 2026 per EVMN's latest filing, from 16699000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 16699000.0 in Q4 2025 and bottomed at 27503000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 21653250.0 across 3 years, with a median of 21205500.0 in 2024.
- Annual changes were most pronounced in 2025 — Cash from Operations increased 9.79% — and 2026, when it declined 15.08%.
- Evommune's Cash from Operations stood at 18512000.0 in 2024, then gained by 9.79% to 16699000.0 in 2025, then sank by 64.7% to 27503000.0 in 2026.
- Business Quant data shows EVMN's Cash from Operations at 27503000.0 in Q1 2026, 16699000.0 in Q4 2025, and 23899000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Evommune | 445.19 Mn | 244.40 Mn | - | -20.32 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -20.32 Mn |
| Mar 31, 2026 | -27.50 Mn |
| Dec 31, 2025 | -16.70 Mn |
| Sep 30, 2025 | -9.64 Mn |
| Jun 30, 2025 | -26.21 Mn |
| Mar 31, 2025 | -23.90 Mn |
| Dec 31, 2024 | -18.51 Mn |